{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"57.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"title":"IDH1/2 mutation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.4"},{"groupId":"OG001","value":"45.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"title":"FLT3 mutation"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"143"}],"units":"Participants"}],"description":"Response was based on physical examination, bone marrow results and hematology values according to the revised guidelines by the IWG for AML:\n\nCR: No morphologic evidence of AML and ANC ≥ 10³/μL, platelets ≥ 10⁵/μL, RBC transfusion independence, and bone marrow with \\< 5% blasts, absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease.\n\nCRi: All criteria as CR except for residual neutropenia \\< 10³/μL or thrombocytopenia \\< 10⁵/μL. If all criteria for CR are met except RBC transfusion independence, CRi criteria is met.\n\nParticipants who had no IWG disease assessments were considered to be non-responders.\n\nResponse was analyzed in participants with the following mutations:\n\n* Isocitrate dehydrogenase 1 and 2 (IDH1/2) mutation\n* FMS-like tyrosine kinase 3 (FLT3) mutation","groups":[{"description":"Participants received matching placebo to venetoclax orally once a day (QD) plus cytarabine 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.","id":"OG000","title":"Placebo + Low Dose Cytarabine (LDAC)"},{"description":"Participants received venetoclax 600 mg orally once a day plus cytarabine 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.","id":"OG001","title":"Venetoclax + Low Dose Cytarabine (LDAC)"}],"paramType":"NUMBER","populationDescription":"Full analysis set participants in each mutation subgroup","reportingStatus":"POSTED","timeFrame":"Response was assessed at the end of Cycle 1 and every 3 cycles thereafter to the end of treatment. Median treatment duration at the 15 February 2019 cut-off date was 1.7 months (range: 0.1-14.2) and 3.9 months (range: 0.0-17.1) in each group respectively.","title":"Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) by Mutation Subgroup","type":"SECONDARY","unitOfMeasure":"percentage of participants"}